Cureus · 2019 · 16 citations · 10 references
MedicineNeurologyPharmacotherapyPain ManagementPain MedicinePsychopharmacologyAnalgesiaAnalgesic PharmacologyCannabinoid PharmacologyCannabinoid AnalgesicsComorbid Chronic PainMood Disorder ComorbidityNeurofibromatosis Type 1Therapeutic Cannabinoid Use
Neurofibromatosis type 1 (NF1) is a common genetic disorder. Pain is a major symptom of this disease which can be secondary to the development of plexiform and subcutaneous neurofibromas, musculoskeletal symptoms (such as scoliosis and pseudoarthrosis), and headaches. Visible neurofibromas add significant psychosocial distress for NF1 patients. Along with the chronic pain, psychosocial distress contributes to associated mood disorders, such as depression and anxiety. Cannabis has been the focus of many studies for treating multiple conditions, including epilepsy, multiple sclerosis, Parkinsonism disease, and many chronic pain conditions. Cannabidiol (CBD) is the major non-psychotropic component of cannabis. CBD has shown anti-inflammatory and analgesic properties, as well as having mood stabilizer and anxiolytic effects. In this report, we present the use of cannabidiol (CBD) for the management of chronic pain and concomitant mood disorder in an NF1 patient.
10
Prevalence of Neurofibromatosis 1 in German Children at Elementary School Enrollment
Marga Lammert, Jan M. Friedman, Lan Kluwe et al. · Archives of Dermatology · 2005 · 418 citations
Quality-of-Life Impairment in Neurofibromatosis Type 1
P. Wolkenstein, J Zeller, J. Revuz et al. · Archives of Dermatology · 2001 · 210 citations
Kirsten M King, Alyssa M Myers, Ariele J Soroka‐Monzo et al. · British Journal of Pharmacology · 2017 · 156 citations · Full text